TY - JOUR JF - rbmb JO - rbmb.net VL - 10 IS - 2 PY - 2021 Y1 - 2021/8/01 TI - Association of Serum Asymmetric Dimethylarginine with the Severity of Coronary Artery Disease: A Pilot Study TT - N2 - Background: Asymmetric dimethylarginine (ADMA), an inhibitor of nitric oxide synthase (NOS), has been implicated in endothelial dysfunction and atherogenesis. Though there is much evidence linking ADMA with atherosclerosis and adverse cardiovascular events, only a few studies have established the independent relationship between elevated ADMA and the angiographic extent of coronary artery disease (CAD). The aim of the study was to analyze serum ADMA levels in patients with varied extent and severity of coronary atherosclerosis and to see whether the levels of ADMA in male and female participants vary significantly. Methods: We analyzed 40 individuals with obstructive CAD, including men and women, between the ages of 30 and 60. According to their coronary angiographic reports, the participants were divided into four groups: minor CAD, single vessel disease (SVD), double vessel disease (DVD) group and triple vessel disease (TVD). Then, serum ADMA levels was measured and compared among these groups. Results: ADMA level was significantly higher in patients with TVD (167.74±16.69) than those in the DVD (159.46±10.40), SVD (149.54±16.39) and minor CAD (144.5± 24.16) group (p-value= 0.0001). There was no significant difference in ADMA levels between male and female participants (p= 0.534). Conclusions: ADMA concentration in the serum may be useful in identifying whether CAD correlates significantly to the extent and severity of coronary atherosclerosis. SP - 302 EP - 306 AU - Goudhaman, Lakshmi AU - Jagadeesan, Anusha Raja AU - Sundaramoorthi, Saranya AU - Thotla, Spandana AU - Mohan, Surapaneni Krishna AD - Department of Biochemistry, Panimalar Medical College Hospital & Research Institute, Poonamallee, Chennai-600123, India. KW - ADMA KW - CAD KW - Endothelial dysfunction KW - NOS KW - Atherosclerosis. UR - http://rbmb.net/article-1-654-en.html DO - 10.52547/rbmb.10.2.302 ER -